http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 송관규 ( G) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
신장 조직 검사에서 사구체 면역침착을 보인 베게너 육아종증 1예
서영진 ( Young Jin Seo ),김윤정 ( Yoon Jung Kim ),문지미 ( Ji Mi Moon ),최혜윤 ( Hae Yoon Choi ),우진현 ( Jin Hyun Woo ),최성재 ( Seong Jae Choi ),이영호 ( Young Ho Lee ),지종대 ( Jong Dae Ji ),정운용 ( Woon Yong Jung ),송관규 ( G 대한신장학회 2009 Kidney Research and Clinical Practice Vol.28 No.6
Rapidly progressive glomerulonephritis (RPGN) in Wegener`s granulomatosis patients typically has been characterized by pauci-immune glomerulonephritis (PIGN). In some patients, however, significant amount of glomerular immune deposits was detected and reported that they may have poor prognosis. A 30 year-old-female visited due to the skin rash of both lower extremities, arthralgia and nasal stiffness. She had sinusitis, lung opacity, and proteinuria. Serologic PR-3 ANCA was positive and histologic findings of nasal cavity and lung also showed necrotizing vasculitis and granuloma. Thus we could diagnose Wegener`s granulomatosis. However, gross hematuria developed and renal function worsened in spite of treatment with high dose prednisolone and oral cyclophosphamide. Therefore we performed a kidney biopsy. The kidney biopsy showed crescentic glomerulonephritis with Ig A deposition in the mesangium. We experienced a case of Wegener`s granulomatosis patient with significant IgA deposition in glomeruli. We report this case with brief review of the literature.
-
Ciprofloxacin의 각종 감염증에 대한 임상효과에 관한 연구
강경호,송관규,유혜경,강숙경,김민자,박승철,김진호,김대원 대한감염학회 1987 감염 Vol.19 No.4
85 patients 37M and 48F, ranging in age between 18-75yrs(39±16), were treated with Ciprofloxacin at daily odse of 100㎎ bid Ⅳ (49) or 500㎎ bid p.o (30), or combined use (6) Infections included: pneumonia (19) bronchitis (15), pharyngotonilitis (1), GI tract infection (15), acute pyelonephritis (26), cystitis (2), sepsis (6), osteomyelitis (1). Severity and mode of infection were; severe 13, moderate 71, mild 1 and acute form 82, chronic 2, recurrent 1. Duration of symptoms before therapy was 4.8±4.5 days and total dose, Duration of Drug were Ⅳ: 2882±1018㎎ 7.1±2.4 dyas oral: 7167±1858㎎, 7.2±1.9 days Ⅳ and oral: 1600±858㎎/4500±1039㎎⁴±0.9/4.5±1.5 days. Isolated major organisms were; 1) pneumonia (19)-k. pneumonia (7), E. cloaceae (4), S. pneumonia(3), P. aeruginosa (2), 2) Bronchitis (15)-S. pneumonia (8), S. aureus (2), E. cloaceae (2), K. Oxytoca (2). 3) GI tract infection(15)-s. typhi (14), S. parathphi (1). 4) acute pyelonephritis (26)-E. coli (17), P. aeruginosa (4), Enterococcus (2), P. mirabilis (1). 5) cystitis (2)-E. coli (1), P. aeruginosa (1). 6) Sepsis (6)-E. coli (6), K. pneumonia (1). 7) osteomyelitis (1)-S. epidermis (1). Clinical result were resolution (64 case-75%), improvement (16-18.3%), undetermined (1-1.1%) failure (4-4.7%). Therapy result were as follows: 66 case (77.7%) were completely resolved 1 case of undetermined course in CVA with pyelonephritis. 14 case (16.5%) of partial response were 6 cases of RTI, 5 case of UTI, 5 case of thphoid fever underlying idsease; rectal cancer 1 Diabetes mellitus 4). 4 case (4.7%) of failure were 2E. coli pneunonia witn liver cirrhosis, 1 s. epidermis osteomyelitis with lymphoma and 1 enterococcus sepsis. Over all efficacy of therapy was 94.2% in 85 cases. Adverse reaction was observed in 1 patient which was fever and rash.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
